source
- FDA advisory panel backs Replimune’s melanoma immunotherapy combined with OpdivoThe FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10-3 to recommend Replimune’s RP1 immunotherapy, used together with Bristol Myers Squibb’s Opdivo, for patients with advanced…
- Arvinas CEO outlines strategy to rebuild pipeline after lead asset departureIn a recent episode of the Denatured podcast, Arvinas President and CEO Randy Teel discussed how the company is shifting focus to an early‑stage pipeline after its lead asset was out‑licensed or di…